U.S. stock market anomaly | Hims & Hers Health (HIMS.US) to introduce exclusive oral testosterone therapy, stock price rises over 7%

Wisdom Financial APP learned that on Wednesday, Hims & Hers Health (HIMS.US) stock price rose, up more than 7% as of the time of writing, trading at $51.39. On the news front, the company announced that in 2026, it will collaborate with the testosterone therapy innovation leader Marius Pharmaceuticals to exclusively launch an oral testosterone drug, KYZATREX, on its platform. This drug has been approved by the US Food and Drug Administration and does not require injection, making it more convenient to use. According to clinical data, KYZATREX can help up to 96% of men restore normal testosterone levels while doubling "free testosterone". Free testosterone is considered to be closely related to energy, drive, and physical performance, and this drug maintains a low rate of adverse reactions while enhancing effectiveness.